Status: current, Sufficiently defined by necessary conditions definition status (core metadata concept). Date: 30-Sep 2021. Module: SNOMED CT core
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 4634449017 | Product containing precisely pramipexole (as pramipexole dihydrochloride) 260 microgram/1 each prolonged-release oral tablet (clinical drug) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 4634450017 | Pramipexole (as pramipexole dihydrochloride) 260 microgram prolonged-release oral tablet | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 5303751000052112 | pramipexol (som pramipexoldihydroklorid) 260 mikrog, depåtablett | sv | Synonym (core metadata concept) | Active | Only initial character case insensitive (core metadata concept) | SNOMED CT Sweden NRC maintained module (core metadata concept) |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Product containing precisely pramipexole (as pramipexole dihydrochloride) 260 microgram/1 each prolonged-release oral tablet (clinical drug) | Is a | Product containing only pramipexole in oral dose form (medicinal product form) | true | Inferred relationship | Some | ||
| Product containing precisely pramipexole (as pramipexole dihydrochloride) 260 microgram/1 each prolonged-release oral tablet (clinical drug) | Has manufactured dose form | Prolonged-release oral tablet | true | Inferred relationship | Some | ||
| Product containing precisely pramipexole (as pramipexole dihydrochloride) 260 microgram/1 each prolonged-release oral tablet (clinical drug) | Has unit of presentation | Tablet (unit of presentation) | true | Inferred relationship | Some | ||
| Product containing precisely pramipexole (as pramipexole dihydrochloride) 260 microgram/1 each prolonged-release oral tablet (clinical drug) | Plays role | Antiparkinson therapeutic role | true | Inferred relationship | Some | ||
| Product containing precisely pramipexole (as pramipexole dihydrochloride) 260 microgram/1 each prolonged-release oral tablet (clinical drug) | Has precise active ingredient | Pramipexole dihydrochloride (substance) | true | Inferred relationship | Some | 1 | |
| Product containing precisely pramipexole (as pramipexole dihydrochloride) 260 microgram/1 each prolonged-release oral tablet (clinical drug) | Has basis of strength substance (attribute) | Pramipexole (substance) | true | Inferred relationship | Some | 1 | |
| Product containing precisely pramipexole (as pramipexole dihydrochloride) 260 microgram/1 each prolonged-release oral tablet (clinical drug) | Has presentation strength denominator unit (attribute) | Tablet (unit of presentation) | true | Inferred relationship | Some | 1 | |
| Product containing precisely pramipexole (as pramipexole dihydrochloride) 260 microgram/1 each prolonged-release oral tablet (clinical drug) | Has presentation strength numerator unit | mcg | true | Inferred relationship | Some | 1 |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
This concept is not in any reference sets
FHIR